menu
The “Cell Therapy Manufacturing Market (3rd Edition),
The “Cell Therapy Manufacturing Market (3rd Edition),
The “Cell Therapy Manufacturing Market (3rd Edition), 2019-2030

The “Cell Therapy Manufacturing Market (3rd Edition), 2019-2030

Key Inclusions

§ A detailed review of the overall landscape of companiesthat are engaged in the manufacturing of cell-based therapies, includinginformation on the type of cells manufactured (including immune cells(including T cells, dendritic cells, NK cells), stem cells (including adultstem cells, human embryonic stem cells and induced pluripotent stem cells) andothers), source of cells (autologous and allogeneic), scale of manufacturing,type of cell cultures (adherent and suspension), purpose of production(fulfilling in-house requirements and contract services), manufacturingcapabilities / services offered (including R&D, cell culture development,quality testing, packaging, labelling, cell banking, cryopreservation, fill /finish services, and regulatory affairs management), location of headquartersand location of their respective manufacturing facilities.

§ An analysis of the various expansion initiatives undertakenby service providers, in order to augment their respective cell therapymanufacturing capabilities, over the period 2015-2019 (till October), taking intoconsideration parameters, such as year of expansion, type of cells, scale ofoperation, purpose of expansion (facility expansion and new facility), locationof manufacturing facility, and most active players (in terms of number ofexpansion initiatives undertaken).

§ An analysis of the recent partnerships focused on themanufacturing of cell-based therapies, which have been established in theperiod 2014-2019 (till November), based on various relevant parameters, such asthe year of agreement, type of partnership, type of cells, and scale ofoperation (preclinical, clinical and commercial).

§ Informed estimates of the annual commercial and clinicaldemand for cell therapies (in terms of number of cells produced and areadedicated to manufacturing), which were further analyzed based on type ofcells.

§ An estimate of the overall, installed capacity formanufacturing cell-based therapies based on information reported by industrystakeholders in the public domain, highlighting the distribution of theavailable capacity on the basis of scale of operation (clinical andcommercial), size of the organization (small, mid-sized and large firms) andkey geographical regions (North America, EU and Asia Pacific).

§ An in-depth analysis of cell therapy manufacturers using threeversatile representations, namely [A] a three dimensional grid analysis,presenting the distribution of companies on the basis of type of cellsmanufactured, scale of operation and purpose of production, [B] a logolandscape based on the type of cells manufactured, geographical location ofmanufacturer (North America, Europe and Asia Pacific) and type and size oforganization (non-industry players, and small, mid-sized and large companies),and [C] a schematic world map representation, highlighting the geographicallocations of cell therapy manufacturing facilities of both industry andnon-industry stakeholders.

§ A detailed analysis of the various factors that are likelyto influence the pricing of cell-based therapies, featuring different models /approaches that may be adopted by manufacturers while deciding the prices oftheir proprietary offerings.

§ An elaborate discussion on the role of automationtechnologies in improving current manufacturing methods, along with acomparative (qualitive) analysis of cost differences between manual andautomated processes.

§ A qualitative analysis, highlighting the various factorsthat need to be taken into consideration by cell therapy developers whiledeciding whether to manufacture their respective products in-house or engagethe services of a CMO.

§ A discussion on cell therapy manufacturing regulationsacross various geographies, including the North America (focusing on the US),Europe and Asia (focusing on Japan), featuring an analysis of the diversecertifications / accreditations awarded to manufacturing facilities byimportant regulatory bodies across the globe.

§ Elaborate profiles of key players (industry andnon-industry) that offer contract manufacturing services for cell-basedtherapies; each profile includes an overview of the company / organization,information on its manufacturing facilities, service portfolio details, recentpartnerships and an informed future outlook.

§ A discussion on affiliated trends, key drivers andchallenges, which are likely to impact the industry’s evolution, under acomprehensive SWOT framework, which includes a Harvey ball analysis,highlighting the relative effect of each SWOT parameter on the overall marketdynamics.

§ Insights generated in a market-wide survey, featuringinputs solicited from experts who are directly and indirectly involved in thedevelopment and / or manufacturing of cell-based therapies.

 

To request samplepages, please visit this - https://www.rootsanalysis.com/reports/285/request-sample.html

 

Key Questions Answered

§ What is the globaldemand for cell-based therapies?

§ Who are the keymanufacturers (industry / non-industry) of cell-based therapies, across theworld?

§ What are the majorrecent developments (such as partnerships and expansions) in this industry?

§ What kind ofpartnership models are commonly adopted by stakeholders in this domain?

§ What is the current, installedcontract manufacturing capacity for cell therapies?

§ What are the keyfactors influencing the make (manufacture in-house) versus buy(outsource) decision related to cell therapies?

§ What are the keyparameters governing the cost of cell therapy manufacturing?

§ What are important technologyplatforms (available / under development) for cell therapy development andmanufacturing?

§  Whatare the key drivers and growth constraints in cell therapy manufacturing market?

§ How is the currentand future market opportunity likely to be distributed across key marketsegments?

 

You may also be interested in the followingtitles:

1.    Cell and AdvancedTherapies Supply Chain Management Market, 2019-2030

2.    RNAi TherapeuticsMarket (2nd Edition), 2019 – 2030

3.    Gene Therapy Market(3rd Edition), 2019 – 2030

4.    Stem Cell TherapyContract Manufacturing Market, 2019-2030

 

Contact Us

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com